cffbefceeb

Kenneth Smith

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Kenneth Smith

  • uploads///syringe __
    Company & Industry Overviews

    Analyst Ratings for AMAG Pharmaceuticals and Peers in February

    Of the 12 analysts covering AMAG Pharmaceuticals, three have given the stock a “buy” or higher rating, and nine have given it a “hold.”

    By Kenneth Smith
  • uploads///BMY
    Company & Industry Overviews

    How Bristol-Myers Squibb’s Key Products Performed in 1Q18

    Total sales for Bristol-Myers Squibb’s Opdivo increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18.

    By Kenneth Smith
  • uploads///ACOR_
    Company & Industry Overviews

    Exploring Acorda Therapeutics’ Financial Performance

    In fiscal 2017, Acorda Therapeutics (ACOR) generated total revenue of $588.2 million, compared with $519.6 million in fiscal 2016.

    By Kenneth Smith
  • uploads///SRPT
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Stock Performance

    After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.

    By Kenneth Smith
  • uploads///Analysts Reco Ignyta
    Company & Industry Overviews

    Analyst Recommendations for Ignyta and Its Peers in January 2018

    Of the four analysts covering Ignyta in January 2018, all of them have given the stock a “hold” rating. The mean rating for the stock is 3.0 with a target price of $28.

    By Kenneth Smith
  • uploads///Spark pipeline
    Company & Industry Overviews

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.

    By Kenneth Smith
  • uploads///mental health _
    Company & Industry Overviews

    Analysts Rate Voyager Therapeutics and Its Peers in April

    Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.

    By Kenneth Smith
  • uploads///TSRO
    Company & Industry Overviews

    Understanding Tesaro’s Operational Performance

    Tesaro’s (TSRO) selling, general, and administrative expenses increased from $92.98 million in Q2 2017 to $100.03 million in Q2 2018.

    By Kenneth Smith
  • uploads///nerve cell _
    Company & Industry Overviews

    Taking Stock of Biogen’s Recent Performance

    In the third quarter, Biogen’s net product revenue rose year-over-year to $2.78 billion from $2.62 billion.

    By Kenneth Smith
  • uploads///AXDX analysts Reco
    Company & Industry Overviews

    What Analysts Recommend for Accelerate Diagnostics and Peers

    Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///REGN Eylea Sales
    Company & Industry Overviews

    Taking Stock of Regeneron Pharmaceuticals’ Marketed Products

    Globally, Regeneron Pharmaceuticals’ (REGN) Eyelea generated $5.9 billion in sales in fiscal 2017 compared with $5.1 billion in fiscal 2016.

    By Kenneth Smith
  • uploads///ABBV
    Company & Industry Overviews

    Analyzing AbbVie’s Financial Performance

    AbbVie (ABBV) generated net revenue of $7.9 billion in 1Q18 compared to $6.5 billion in 1Q17.

    By Kenneth Smith
  • uploads///SYK
    Company & Industry Overviews

    Understanding Stryker’s Operational Performance

    Stryker (SYK) incurred SG&A (selling, general, and administrative) expenses of $1.19 billion in the second quarter.

    By Kenneth Smith
  • uploads///GILD
    Company & Industry Overviews

    What Does Gilead Sciences’ Bottom-Line Trend Indicate?

    Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter.

    By Kenneth Smith
  • uploads///syk segments
    Company & Industry Overviews

    Exploring Stryker’s Business Segments

    Products under the Orthopedics segment include implants used for hip and knee joint replacements and extremities surgeries.

    By Kenneth Smith
  • uploads///ISRG
    Company & Industry Overviews

    How Intuitive Surgical Stock Has Performed in the Last Month

    From a low of $376.92 on January 4, Intuitive Surgical (ISRG) stock rose to a high of $581.12 on October 1.

    By Kenneth Smith
  • uploads///Nektar Revenue Trend
    Company & Industry Overviews

    A Look at Nektar Therapeutics’ Financial Performance

    Diversified revenue streams Nektar Therapeutics’ (NKTR) total revenue includes product sales, royalty revenue, non-cash revenue related to the sale of future royalties, and license and collaboration revenue. Nektar had product sales of $4.4 million in 3Q17, compared with $144.7 million in 3Q16. Between 3Q16 and 3Q17, its royalty revenue rose from $5.5 million to $9.3 million, and its license […]

    By Kenneth Smith
  • uploads///VSTM RD
    Company & Industry Overviews

    A Look at Verastem’s Operational Performance

    Verastem (VSTM) incurred general and administrative expenses of $15.8 million in Q2 2018 compared to $4.4 million in Q2 2017.

    By Kenneth Smith
  • uploads///TSRO
    Company & Industry Overviews

    Gauging Analysts’ Views on Tesaro Stock

    In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.

    By Kenneth Smith
  • uploads///AKRX
    Company & Industry Overviews

    Analyzing the Cash Flows and Valuation Metrics of Akorn

    Akorn (AKRX) used up $31.6 million in operating activities in 1Q18. In comparison, the company generated operating cash flow of $126.6 million in 1Q17.

    By Kenneth Smith
  • uploads///chair _
    Earnings Report

    Dentsply Sirona’s Segments: Q2 2018 Performance

    Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%.

    By Kenneth Smith
  • uploads///Marinus risks
    Company & Industry Overviews

    Key Risks Facing Marinus Pharmaceuticals in December 2017

    Since inception in 2003, Marinus Pharmaceuticals (MRNS) has focused on the development of ganaxalone.

    By Kenneth Smith
  • uploads///Insys revenue
    Company & Industry Overviews

    A Look at Insys Therapeutics’ Financial Performance

    Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales.

    By Kenneth Smith
  • uploads///Axovant clinical pipeline
    Company & Industry Overviews

    Investors Still Excited about Axovant

    Axovant is focusing on gene therapy candidates AXO-Lenti-PD and AXO-AAV-OPMD.

    By Kenneth Smith
  • uploads///CELG Revlimid
    Company & Industry Overviews

    Analyzing the Performance of Celgene’s Hematology Portfolio

    Celgene’s total worldwide sales of the hematology/oncology category increased from $2.7 billion in 1Q17 to $3.1 billion in 1Q18.

    By Kenneth Smith
  • uploads///pills _
    Earnings Report

    How AbbVie Fared in Q2 2018

    Driven by growth in Humira, Imbruvica, and Mavyret sales, AbbVie (ABBV) delivered strong Q2 2018 results on July 27.

    By Kenneth Smith
  • uploads///BGNE
    Company & Industry Overviews

    Do Analysts See Any Upside in BeiGene Stock?

    Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”

    By Kenneth Smith
  • uploads///Spark ana reco
    Company & Industry Overviews

    What Spark Therapeutics’ Valuation Trend Indicates

    Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

    By Kenneth Smith
  • uploads///CELG Otezla
    Company & Industry Overviews

    Performance of Celgene’s Inflammation and Immunology Products

    Total worldwide sales of Celgene’s other products—including Idhifa, Thalomid, and Istodax—increased from $226.0 million in 1Q17 to $229.0 million in 1Q18.

    By Kenneth Smith
  • uploads///GERN
    Company & Industry Overviews

    Analyzing Geron’s Financial Performance

    In Q1 2018, Geron’s (GERN) license fee and royalty revenue fell YoY (year-over-year) to $318,000 from $537,000, with license fee revenue falling YoY to $248,000 from $409,000.

    By Kenneth Smith
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    Key Risks Facing Sucampo Pharmaceuticals in 2017

    Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

    By Kenneth Smith
  • uploads///Sucampo pipeline pre
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Research Pipeline in December 2017

    Sucampo Pharmaceuticals (SCMP) recently completed a Phase 3 study for the alternate sprinkle formulation of Amitiza (lubiprostone) in adults with CIC (chronic idiopathic constipation).

    By Kenneth Smith
  • uploads///Novavax RSV Pipeline
    Company & Industry Overviews

    Exploring Novavax’s Vaccine Candidates for RSV

    According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

    By Kenneth Smith
  • uploads///Spectrum Pharmaceuticals Pipeline
    Company & Industry Overviews

    An Overview of Spectrum Pharmaceuticals’ Drug Pipeline

    Spectrum Pharmaceuticals (SPPI) obtained exclusive rights to commercialize Poziotinib from Hanmi Pharmaceutical (HANPF) under an in-license agreement in 2015.

    By Kenneth Smith
  • uploads///Folotyn
    Company & Industry Overviews

    Spectrum Pharmaceuticals’ Product Licensing Agreements

    In 2012, Spectrum Pharmaceuticals (SPPI) acquired the rights to market Zevalin outside the US from Bayer for 19 million euros.

    By Kenneth Smith
  • uploads///coinsquare market share
    Company & Industry Overviews

    Riot Blockchain’s Recent Investments in the Cryptocurrency Space

    In October 2017, Riot Blockchain (RIOT) acquired a 52% stake in Tess, a developer of blockchain solutions for telecom (telecommunications) companies.

    By Kenneth Smith
  • uploads///BAX
    Company & Industry Overviews

    Analyzing Baxter International’s Operational Performance

    Baxter International’s net interest expense decreased from $13 million in the second quarter of 2017 to $11 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///SYK
    Company & Industry Overviews

    What Stryker’s Bottom-Line Trend Indicates

    Stryker’s (SYK) net other expense decreased from $54.0 million in the third quarter of 2017 to $42.0 million in the latest quarter.

    By Kenneth Smith
  • uploads///Danaher ana reco
    Company & Industry Overviews

    Analyzing the Performance of Danaher’s Dental Business

    Danaher Corp.’s (DHR) enterprise value is $85.21 billion, and its enterprise-value-to-revenue ratio is 4.42.

    By Kenneth Smith
  • uploads///ATNX
    Company & Industry Overviews

    How’s Athenex’s Financial Performance?

    In fiscal 2017, Athenex (ATNX) generated total revenues of $38 million—compared to $20.5 million in fiscal 2016.

    By Kenneth Smith
  • uploads///Novavax Revenue Growth
    Company & Industry Overviews

    Chart in Focus: Novavax’s Financial Position in 2017

    Novavax (NVAX) generated revenues of $8.4 million in 3Q17 compared with $3.2 million in 3Q16.

    By Kenneth Smith
  • uploads///VRAY RD
    Company & Industry Overviews

    Exploring ViewRay’s Operational Performance

    ViewRay incurred general and administrative expenses of $10.5 million in the second quarter compared to $7.46 million in the second quarter of 2017.

    By Kenneth Smith
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///diabetes _
    Company & Industry Overviews

    Tandem Diabetes Care Continues Its Strong Performance in Q2 2018

    Tandem Diabetes Care’s (TNDM) t:slim X2 with Basal-IQ, which is its automated insulin delivery algorithm, was approved by the FDA in June.

    By Kenneth Smith
  • uploads///NKTR
    Company & Industry Overviews

    How Was Nektar Therapeutics’ Top-Line Performance?

    In the first quarter, Nektar Therapeutics (NKTR) generated total revenues of $38 million compared with $24.7 million in the first quarter.

    By Kenneth Smith
  • uploads///ITGR SGA
    Company & Industry Overviews

    The Financial Performance of Integer Holdings Corporation

    The total revenues of Integer Medical Holdings (ITGR) grew from $1.3 billion in fiscal 2016 to $1.4 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///ABMD
    Company & Industry Overviews

    Examining Abiomed’s Gross Margin Trend

    In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.

    By Kenneth Smith
  • uploads///ATNX
    Company & Industry Overviews

    Athenex’s Product Groups and Geographic Performance

    The majority of Athenex’s revenues in Q1 2018 came from API sales, commercial product sales, and license fees.

    By Kenneth Smith
  • uploads///WAT SGA
    Company & Industry Overviews

    Exploring Waters Corporation’s Operational Performance

    Waters Corporation (WAT) incurred selling and administrative expenses of $136.6 million in the second quarter.

    By Kenneth Smith
  • uploads///AZN
    Company & Industry Overviews

    Major Expected Events from AstraZeneca’s R&D in H2 2018

    AstraZeneca has seen major recent product approvals such as Lynparza in Japan for breast cancer and Tagrisso in the EU for lung cancer.

    By Kenneth Smith
  • uploads///ATNX
    Company & Industry Overviews

    Analyzing Athenex’s Cash Flows

    In fiscal 2017, Athenex (ATNX) incurred interest expenses of $5.9 million—compared to $1.8 million in fiscal 2016.

    By Kenneth Smith
  • uploads///GERN
    Company & Industry Overviews

    Exploring Geron’s Financial Performance

    In fiscal 2017, Geron (GERN) generated revenues of $1 million through license fees and royalties compared with $6.1 million in fiscal 2016.

    By Kenneth Smith
  • uploads///BAX
    Company & Industry Overviews

    Baxter International’s Global Business Units in Q1 2018

    Sales for Renal Care increased 10% from $789 million in Q1 2017 to $868 million in Q1 2018.

    By Kenneth Smith
  • uploads///AFAM
    Company & Industry Overviews

    Exploring Almost Family’s Financial Performance

    In 2017, Almost Family (AFAM) generated net service revenue of $796.9 million compared to $623.5 million in 2016.

    By Kenneth Smith
  • uploads///Ignyta Pipeline
    Company & Industry Overviews

    Ignyta’s Drug Pipeline

    Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.

    By Kenneth Smith
  • uploads///Entrectinib profile
    Company & Industry Overviews

    A Close Look at Ignyta’s Licensing Agreement

    Ignyta (RXDX) entered into a licensing agreement with Nerviano Medical Sciences in which Ignyta has exclusive global rights to develop and commercialize entrectinib.

    By Kenneth Smith
  • uploads///Ignyta RD Expenses
    Company & Industry Overviews

    Inside Ignyta’s Financial Performance

    Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.

    By Kenneth Smith
  • uploads///Ignyta risks
    Company & Industry Overviews

    Ignyta and Its Key Risks in 2018

    In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.

    By Kenneth Smith
  • uploads///SGEN
    Company & Industry Overviews

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

    By Kenneth Smith
  • uploads///hospital _
    Earnings Report

    How Boston Scientific Is Expected to Perform in the Third Quarter

    Boston Scientific (BSX) is expected to report its third-quarter earnings on October 24.

    By Kenneth Smith
  • uploads///ALNY
    Company & Industry Overviews

    Why Alnylam’s Clinical Pipeline Seems Promising

    Alnylam Pharmaceuticals’ (ALNY) target indications include genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases.

    By Kenneth Smith
  • uploads///TMO
    Company & Industry Overviews

    Do Analysts See Any Upside for Thermo Fisher Stock?

    Of the 17 analysts covering Thermo Fisher Scientific (TMO), 14 recommend ” buy” or a higher rating, and three recommend “hold.”

    By Kenneth Smith
  • uploads///TMO
    Company & Industry Overviews

    Thermo Fisher Scientific’s Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///hospital _
    Company & Industry Overviews

    Taking Stock of Thermo Fisher as the Year Wraps Up

    In this series, we’ll explore Thermo Fisher’s financials and valuation, and analysts’ views on its stock.

    By Kenneth Smith
  • uploads///cells _
    Company & Industry Overviews

    Taking Stock of BeiGene’s Latest Performance

    BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.

    By Kenneth Smith
  • uploads///ABMD
    Company & Industry Overviews

    Do Analysts See Any Upside for Abiomed Stock?

    In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    Exploring Abiomed’s Latest Performance Trends

    In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.

    By Kenneth Smith
  • uploads///SRPT
    Company & Industry Overviews

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Do Analysts See Any Upside for Vertex Stock?

    Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Vertex Pharmaceuticals’ Gross Margin Trends

    Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Taking Stock of Vertex’s Performance

    Vertex Pharmaceuticals (VRTX) focuses on developing cystic fibrosis therapies and bringing them to market.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Do Analysts See Any Upside for bluebird bio Stock?

    In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Understanding bluebird bio’s Operational Performance

    In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///SAGE
    Company & Industry Overviews

    Sage Therapeutics’ Operational Performance

    In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.

    By Kenneth Smith
  • uploads///nerve cell _
    Company & Industry Overviews

    Sage Therapeutics: Analyzing New Product Candidates

    The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.

    By Kenneth Smith
  • uploads///IONS
    Company & Industry Overviews

    Do Analysts See Any Upside for Ionis Stock?

    Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds.”

    By Kenneth Smith
  • uploads///molecule _
    Company & Industry Overviews

    Taking Stock of Ionis’s Performance

    Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake.

    By Kenneth Smith
  • uploads///woman _
    Company & Industry Overviews

    Taking Stock of DaVita’s Performance

    In the third quarter, DaVita’s total revenue rose YoY (year-over-year) to $2.85 billion from $2.76 billion.

    By Kenneth Smith
  • uploads///BIIB
    Company & Industry Overviews

    Do Analysts See Any Upside for Biogen Stock?

    Of the 29 analysts covering Biogen (BIIB), 20 have given it “buy” or higher ratings, and nine have given it “hold” ratings.

    By Kenneth Smith
  • uploads///ABT
    Company & Industry Overviews

    Abbott Laboratories’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Abbott Laboratories (ABT) is expected to generate revenue of $30.66 billion and $32.21 billion, respectively, compared with revenue of $27.39 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///pill _
    Company & Industry Overviews

    Health Check: How Abbott Laboratories is Positioned

    Abbott Laboratories (ABT) offers products in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Cardiovascular and Neuromodulation Products.

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Do Analysts See Any Upside for Regeneron Stock?

    Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”

    By Kenneth Smith
  • uploads///SGEN
    Company & Industry Overviews

    What Seattle Genetics’ Bottom-Line Trend Indicates

    In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    How’s Seattle Genetics Positioned?

    Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Regeneron Pharmaceuticals’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///ENDP
    Company & Industry Overviews

    How Much Upside Do Analysts Expect in Endo Stock?

    In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///TNDM
    Company & Industry Overviews

    How Tandem Diabetes Care Stock Has Fared in the Last Month

    After a phenomenal run from $2.52 on January 5 to a high of $51.17 on September 13, Tandem Diabetes Care (TNDM) stock slid.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    How Illumina Stock Has Fared in the Last Month

    After witnessing a rise from $209.54 on February 8 to a high of $372.61 on September 28, Illumina (ILMN) stock corrected to $289.50 on October 24.

    By Kenneth Smith
  • uploads///checklist _
    Company & Industry Overviews

    How XRAY’s Performance Has Shaken Out over the Last Month

    Dentsply Sirona stock witnessed a steady uptick in November, rising from $34.58 on November 6 to $37.78 on November 30.

    By Kenneth Smith
  • uploads///HOLX
    Company & Industry Overviews

    How Hologic Stock Has Fared in the Last Month

    After rising from $36.53 on April 9, 2018, to $42.91 on July 31, 2018, Hologic (HOLX) stock slid to $37.90 on October 29, 2018.

    By Kenneth Smith
  • uploads///EW
    Company & Industry Overviews

    How Has Edwards Lifesciences Stock Fared in the Last Month?

    After witnessing strong gains from $115.41 on January 4, 2018, to a high of $174.10 on September 28, 2018.

    By Kenneth Smith
  • uploads///hospital _
    Company & Industry Overviews

    How These Medical Equipment Stocks Have Fared in the Last Month

    In December 2018, of the total 15 analysts covering Align Technology, 13 analysts have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///molecule _
    Company & Industry Overviews

    Taking Stock of Sangamo’s Financial Performance

    In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.

    By Kenneth Smith
  • uploads///cells _
    Company & Industry Overviews

    An Overview of Array BioPharma Stock

    Array BioPharma generated total revenue of $56.91 million in the first quarter of fiscal 2019.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Analysts Remain Bullish on Illumina Stock

    In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Gross Margin Trend

    Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Geographical Performance

    For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.

    By Kenneth Smith
  • uploads///hypertension _
    Company & Industry Overviews

    Taking Stock of Edwards Lifesciences’ Performance

    A strong operational performance and steady uptick in Edwards Lifesciences’ stock price has kept investors interested in the stock in 2018.

    By Kenneth Smith
  • uploads///XRAY
    Company & Industry Overviews

    What Does Dentsply’s Bottom-Line Trend Indicate?

    Dentsply Sirona’s interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.